Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar 10;31(8):1089-96.
doi: 10.1200/JCO.2012.43.9422. Epub 2013 Feb 11.

MET as a possible target for non-small-cell lung cancer

Ahad A Sadiq  1 , Ravi Salgia
Affiliations
Review

MET as a possible target for non-small-cell lung cancer

Ahad A Sadiq et al. J Clin Oncol. .

Abstract

Lung cancer is a heterogeneous group of disorders that is now being subdivided into molecular subtypes with dedicated targeted therapies. The MET receptor tyrosine kinase has been identified as aberrantly overexpressed, potentially having activating mutations, and amplified in certain subsets of lung cancers. The ligand hepatocyte growth factor (HGF) can also be overexpressed in lung cancer or expressed in stroma, and both the MET receptor and the HGF ligand can be targets for therapeutics, especially in lung cancer. Activation of MET leads to a plethora of biochemical and biologic changes both in normal and cancerous cells. Preclinically, it has been shown that silencing or inactivating MET leads to decreased viability of cancer cells. There are a number of compounds against MET/HGF in clinical trials that have been shown to be active in lung cancers. This review will summarize the biology of MET as well as its therapeutic inhibition in lung cancer.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Synergism between MET/recepteur d'origine nantais (RON) and epidermal growth factor receptor (EFGR). mTOR, mammalian target of rapamycin.
Fig 2.
Fig 2.
Targeting of the hepatocyte growth factor (HGF)/MET pathway. HGF-dependent activation of the MET pathway can be disrupted through extracellular therapies that interfere with HGF binding to MET. Intracellular approaches can inhibit HGF-dependent and -independent mechanisms that lead to phosphorylation of MET kinase substrates.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002;297:102–104. - PubMed
    1. Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 1999;400:468–472. - PubMed
    1. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4:199–207. - PubMed
    1. Huettner CS, Zhang P, Van Etten RA, et al. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet. 2000;24:57–60. - PubMed
    1. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 2002;109:321–334. - PubMed

Publication types

MeSH terms